IMGT Co.,Ltd. engages in researching and developing of an ultrasound-guided therapy technology for genetic therapy and drug delivery systems. It develops IMGT-LPS, a technology that injects ultrasound-sensitive nanoparticles in the form of liposome-wrapped pharmacological substances into the body and releases drugs by irradiating ultrasound to the target area(tumor); IMGT-EMB, a nanoparticle for chemoembolization of liver cancer; IMGT-TSD, a targeted sonodynamic therapy that induces immune boosting mechanism by applying ultrasonic stimulation to the cancerous area; and IMGT-FUS, a device for non-invasive treatment. The company was founded in 2010 and is based in Seongnam-si, South Korea.
Metrics to compare | 456570 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship456570PeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −4.4x | −0.5x | |
PEG Ratio | 0.00 | −0.09 | 0.00 | |
Price/Book | 0.0x | 2.1x | 2.6x | |
Price / LTM Sales | 0.0x | 19.2x | 3.3x | |
Upside (Analyst Target) | 0.0% | 28.1% | 43.4% | |
Fair Value Upside | Unlock | −1.1% | 7.1% | Unlock |